Deucravacitinib in plaque psoriasis: long-term safety and efficacy, M. Lebwohl et al.

Vitamin D and psoriasis: The Tromsø Study 2015–16, M. Jenssen et al.

23 1108 video

Novel biomarkers in the early diagnosis of malignant melanoma, J. Peña-Martín et al.

Izuforant in cholinergic urticaria, E. Grekowitz et al.

BE BRIGHT 3-Year Safety, K.B. Gordon et al.

Monitoring anti-TNFα treatment, A. Abhishek et al.

The HOME ‘how-to’ guide, K.S. Thomas et al

Global core dataset for hidradenitis suppurativa registries, H.E. Wainman et al.

Topical permethrin 5% vs. benzyl benzoate 25% in scabies, D. Meyersburg et al

Epidemiology of alopecia areata, M. Augustin et al

UPGRADE Core Domain Set Consensus for Pyoderma Gangrenosum Clinical Trials, M.E. Jacobson et al

Safety of biologic therapy in combination with methotrexate in psoriasis, J.J. Lluch-Galcerá et al.

Macrophages in graft-versus-host disease, J. Strobl et al.

Omalizumab in BP: French national multicentre retrospective study, R. Chebani et al.

Identification of potential common genetic modifiers of neurofibromas, L. Pacot et al.

Core domain set for cutaneous neurofibromas in NF1, L. Fertitta et al

Risk factors for subsequent primary melanoma, J. Smith et al.

Relative efficacy of systemic treatments for eczema, A.M. Drucker et al.

Safety, tolerability, pharmacokinetics and efficacy of HB0017, C. Jiang et al.

A pharmacogenetic study of psoriasis, H. Zhang et al.

Integrated medicine for filarial lymphoedema, S.R. Narahari et al

Hidradenitis suppurativa tarda: defining an understudied elderly population, van der Weijden et al.

IL-17A+ mast cells in HS, C-B Chu et al.

Dupilumab improves sleep in atopic dermatitis, J.F. Merola et al.

The HOME implementation roadmap, Y.A. Leshem et al.

Metformin suppresses inflammation and cellular metabolism in HS, A. Petrasca et al.

Short anagen hair syndrome is associated with WNT10A variants, N. Cesarato et al.

Melanoma survival trend shifts in Sweden, S. Vikström et al.

Scalp hair regrowth in severe AA treated with baricitinib in two phase III trials, B. King et al.